跳至主要内容
临床试验/NCT04751708
NCT04751708已完成不适用

Endovascular Treatment for Acute Basilar Artery Occlusion - a Multicenter Randomized Clinical Trial

The First Affiliated Hospital of University of Science and Technology of China1 个研究点 分布在 1 个国家目标入组 340 人开始时间: 2021年2月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
340
试验地点
1
主要终点
a modified Rankin Score of 0-3

研究概览

简要总结

Rationale: Recently, two prospective multicenter RCT reported a potential beneficial effect of endovascular thrombectomy (EVT) in patients with an acute symptomatic basilar artery occlusion (BAO). However, the high rate of crossover in BEST study and the long-term of recruitment in BASICS study influenced the validity of the results. Besides, a recently prospective clinical registry with large sample size (BASILAR) showed a significantly beneficial effect of EVT in BAO patients.

Objective: To assess the effect of EVT in addition to best medical management (BMM) compared to BMM alone, in patients with BAO, caused by a CTA/MRA confirmed occlusion of the basilar artery on functional and safety outcome.

Study design: This is a parallel group, randomized clinical trial of EVT with BMM versus BMM. The trial has observer blind assessment of the primary outcome and of neuro-imaging at baseline and follow up.

Study population: Patients with acute ischemic stroke and a confirmed basilar artery occlusion by CTA/MRA.

Main study parameters/outcomes: The primary effect parameter will be favourable outcome at day 90 defined as a modified Rankin Score (mRS) of 0-3. The estimate will be adjusted for the known prognostic variables age, pre-stroke mRS, time from onset to randomization, stroke severity (NIHSS) and collaterals and adjusted and unadjusted estimates with corresponding 95% confidence intervals will be reported.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Symptoms and signs compatible with ischemia in the basilar artery territory;
  • Basilar artery occlusion confirmed by CTA/MRA/DSA;
  • Age of 18 years or older;
  • Time from stroke onset to randomization within 12 hours of estimated time of basilar artery occlusion (defined as the sudden onset of stroke symptoms consistent with acute occlusion of the basilar artery (e.g. not considering any previous minor prodromal symptoms) as adjudicated by two local experienced neurologists). If symptoms of sudden deterioration are not witnessed (e.g. wake-up or unwitnessed strokes) the time that the patient was last known to be without any major neurological deficits (such as moderate or severe weakness, stupor, coma) will be used as the time of stroke onset.
  • Written informed consent;
  • National Institutes of Health Stroke Scale (NIHSS) score ≥10 at the time of neuroimaging

排除标准

  • Pre-existing dependency with mRS ≥3 for patients<80 years; premorbid mRS≥1 for patients≥80 years;
  • bilateral mydriasis;
  • Pregnancy; if a woman is of childbearing potential a urine or serum beta HCG test is positive;
  • Severe contrast allergy or absolute contraindication to iodinated contrast;
  • Participation in other clinical trials;
  • Systolic pressure >185 mmHg or diastolic pressure >110 mmHg, and cannot be controlled by antihypertensive drugs;
  • Known genetic or acquired bleeding constitution, lack of anticoagulant factors, or oral anticoagulant drugs and INR > 1.7;
  • Blood glucose < 2.7 or >22.2 mmol / L; platelet count < 50×109 / L, or hematocrit < 25%;
  • Life expectancy < 1 year;
  • Patients that cannot complete 90-day follow-up (e.g. no fixed residence, overseas patients, etc.);
  • Acute ischemic cerebral infarction within 48 hours after major surgery (patients can be enrolled if more than 48 hours);
  • Premorbid cerebrovascular inflammation;
  • Premorbid nervous system disease or mental disorders hindering the assessment of the disease; Imaging exclusion criteria
  • CT/MR shows intracranial hemorrhage (patients with microbleeds on MR can be included if lesion diameter ≤5mm);
  • CTA/MRA/DSA shows the artery is seriously tortuous, variability or dissection, and thrombectomy device cannot reach the target vessel;
  • PC-ASPECTS on CT/CTA-Source Images/MRI-DWI <6 for patients<80 years (<8 for patients ≥80 years);
  • CT or MR shows the cerebellar infarction with obvious space occupying effect and obvious compression of the fourth ventricle;
  • Complete bilateral thalami or bilateral brainstem infarction confirmed by CT/MR;
  • Occlusion of both anterior and posterior circulation confirmed by CTA/MRA/DSA;
  • Intracranial tumors (except small meningiomas).

结局指标

主要结局

a modified Rankin Score of 0-3

时间窗: 90 (± 14 days) after procedure

Favourable outcome at day 90 (± 14 days)

次要结局

  • Modified Rankin Score(90 (± 14 days) after procedure)
  • mortality(90 (± 14 days) after procedure)
  • a modified Rankin Score of 0-2(90 (± 14 days) after procedure)
  • NIHSS score(5-7 days after procedure)
  • symptomatic intracerebral hemorrhage (ICH)(within 72 hours after procedure)

研究者

发起方
The First Affiliated Hospital of University of Science and Technology of China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Wei Hu

Professor

The First Affiliated Hospital of University of Science and Technology of China

研究点 (1)

Loading locations...

相似试验